Skip to main content
    G

    Geron Corporation (GERN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.94
    -0.03 (-2.60%)

    Market Cap: $622.98M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Geron Corporation (GERN) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Geron (GERN) trades at 2.9x sales and 2.8x book value. Its P/B of 2.8x is below its 5-year median of 4.8x. Its forward P/E is 48.3x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E48.3x
    Price to sales2.9x
    Price to book2.8x
    PEGN/A
    FCF yield-14.4%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/B is 17.6% below 3.4x.

    MultipleCurrent5-year median10-year median
    P/B2.8x4.8x3.4x
    Medians of month-end values through Oct 2026: 51 months (5-year) and 111 months (10-year).

    Valuation History

    Over the 6 of the 10 year ends shown that have a P/S, its P/S ranged from 30.0x in 2024 to 566.3x in 2019. 2024 was the lowest of those years.

    Year endPriceP/SP/B
    2025$1.32N/A3.9x
    2024$3.5430.0x8.2x
    2023$2.11N/A5.1x
    2022$2.42N/A12.3x
    2021$1.22288.9x3.2x
    2020$1.59N/A2.4x
    2019$1.36566.3x2.0x
    2018$1.00164.5x1.0x
    2017$1.80269.1x2.8x
    2016$2.0753.4x2.7x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About GERN

    What is GERN's forward P/E ratio?

    Geron has a forward P/E ratio of 48.3x.

    Is GERN stock overvalued?

    GNG's valuation label for GERN is Undervalued.

    What is GERN's price to sales ratio?

    Geron has a price to sales ratio of 2.9x.